“Clinically-validated and minimally-invasive treatment options for patients with both coronary artery disease and diabetes has represented a significant unmet clinical need for the diabetes community for quite some time,” said Dr. Scott W. Lee, M.D., clinical professor of medicine at Loma Linda University Medical Center near Los Angeles and medical director of global clinical research for Medtronic Diabetes in Northridge, Calif., who will present the results of the diabetes analysis. “Considering the challenges that are presented when treating diabetes patients with CAD, physicians can have confidence in the consistently low event rates in both patients with and without diabetes when using this device.”The analysis will also feature additional outcomes for important safety measures, comparing insulin-dependent- and non-insulin-dependent diabetes patients to patients without diabetes. Rates are similar among non-insulin-dependent diabetes patients and patients without diabetes.
|RESOLUTE Pooled Diabetes Analysis: Two-Year Outcomes|
|Insulin-Dependent||Non-Insulin Dependent||Patients Without|
|Endpoint*||Diabetes Patients||Diabetes Patients||Diabetes|
|* Endpoint Key|
|• TLR = target lesion revascularization (a repeat procedure to treat the same arterial segment)|
|• CD/TVMI = cardiac death/target vessel myocardial infarction|
|• Def/Prob ST = definite/probable stent thrombosis as defined by the Academic Research Consortium (ARC)|
ABOUT MEDTRONICMedtronic, Inc. ( www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health and extending life for millions of people around the world. Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results. 1 Tan, Meng Hee. From Research to Practice Diabetes and Coronary Heart Disease. Diabetes Spectrum1999; 12: 80-83. http://journal.diabetes.org/diabetesspectrum/99v12n2/pg81.htm 2 Standard risk was defined as excluding the following characteristics: bifurcation, saphenous vein graft (SVG), in-stent restenosis (ISR), acute myocardial infarction (AMI) within 72 hours, left ventricular ejection fraction (LVEF) of less than 30%, unprotected left main disease, atherosclerosis in three or more vessels, renal impairment, total lesion length per vessel of greater than 27 mm, two or more lesions per vessel, lesion with thrombus, or lesion with total occlusion.